- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05686356
A Pan-TB Regimen Targeting Host and Microbe (panTB-HM)
May 14, 2024 updated by: The Aurum Institute NPC
A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)
This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility.
The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial.
It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
352
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Professor Robert Wallis
- Phone Number: +1 (860) 271-6745
- Email: rwallis@auruminstitute.org
Study Contact Backup
- Name: Mr Don L Mudzengi
- Phone Number: +27833697946
- Email: dmudzengi@auruminstitute.org
Study Locations
-
-
-
Maputo, Mozambique
- Recruiting
- Instituto Nacional de Saúde
-
Contact:
- Dr Emilia Fumane, MD
- Email: emilia.fumane@ins.gov.mz
-
Principal Investigator:
- Celso Khosa, MD
-
-
-
-
-
Durban, South Africa, 4015
- Recruiting
- Clinical HIV Research Unit
-
Contact:
- Shakira Dr Rajaram
- Phone Number: +27824221631
- Email: shrajaram@witshealth.co.za
-
Contact:
- Nonhlanhla Gahima
- Phone Number: +27877022581
- Email: ngahima@witshealth.co.za
-
Principal Investigator:
- Shakira Rajaram, MD
-
Klerksdorp, South Africa, 2571
- Not yet recruiting
- The Aurum Institute, Gavin J Churchyard Legacy Centre (Klerksdorp Clinical Research Centre)
-
Contact:
- Mgcini Moyo, MD
- Phone Number: +27615218350
- Email: mmoyo@auruminstitute.org
-
Principal Investigator:
- Mgcini Moyo, MD
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2092
- Recruiting
- Clinical HIV Research Unit
-
Contact:
- Elizabeth Monari
- Phone Number: +27812863310
- Email: emonari@witshealth.co.za
-
Contact:
- Mohammed Dr Rassool, MD
- Phone Number: +2711 276 8800
- Email: mrassool@witshealth.co.za
-
Principal Investigator:
- Mohammed Dr Rassool, MD
-
Tembisa, Gauteng, South Africa, 1632
- Recruiting
- The Aurum Institute: Tembisa Clinical Research Centre
-
Contact:
- Don Mudzengi, MSc
- Phone Number: +27 83 369 7946
- Email: dmudzengi@auruminstitute.org
-
Contact:
- Salome Dr Charalambous, MD
- Phone Number: +27 82 856 1146
- Email: scharalambous@auruminstitute.org
-
Principal Investigator:
- Salome Charalambous, MD
-
-
North West Provice
-
Rustenburg, North West Provice, South Africa, 0299
- Not yet recruiting
- The Aurum Institute, Rustenburg Clinical Research Centre
-
Contact:
- William Brumskine, MD
- Phone Number: +27723343575
- Email: wbrumskine@auruminstitute.org
-
Principal Investigator:
- William Brumskine, MD
-
-
Western Cape
-
George, Western Cape, South Africa, 6529
- Recruiting
- TASK Eden
-
Contact:
- Alida van Deventer
- Phone Number: +27448733395
- Email: ida@task.org.za
-
Contact:
- Belinda Van Rooyen
- Phone Number: +27448733395
- Email: belinda.vr@task.org.za
-
Principal Investigator:
- Louis Botha, MD
-
-
-
-
-
Mbeya, Tanzania
- Recruiting
- NIMR-Mbeya Medical Research Centre
-
Contact:
- Dr Nyanda Ntinginya, MD, Phd
- Phone Number: +255 25 2503364
- Email: nelias@nimr-mmrc.org
-
Contact:
- Dr Issa Sabi, MD, PhD
- Email: isabi@nimr-mmrc.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 18 to 65 years
- Willing and able to provide signed written consent prior to undertaking any trial-related procedures, or, in the case of illiteracy, witnessed oral consent
- Body weight (in light clothing without shoes) between 30 and 90 kg.
- Radiographic evidence of pulmonary tuberculosis
- Positive Xpert TB/RIF (original or Ultra) for MTB
- RIF susceptibility diagnosed by Xpert TB/RIF, with subsequent culture confirmation
- If sexually active, willing to use an effective contraceptive method for the duration of tuberculosis treatment
- HIV-1 seronegative, or if HIV-1 seropositive, CD4 T cell count ≥100/µl and either receiving ART or willing to start ART during study participation
- SARS-CoV-2 PCR or antigen test negative, or if positive, either fully vaccinated against Covid-19 or with D-dimer <0.8 ug/ml
- Willing to adhere to a diet excluding tyramine-rich foods (certain mold-ripened cheeses and cured meats), and to avoid eating grapefruits and pomelos
Exclusion Criteria:
- Any condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol specified assessments
- Current or imminent (within 24 hr) treatment for malaria.
- Pregnant or nursing
- Is critically ill, and in the judgment of the investigator has a diagnosis likely to result in death during the trial or the follow-up period.
- TB meningitis or spondylitis, or other forms of severe tuberculosis with high risk of a poor outcome as judged by the investigator.
- History of allergy or hypersensitivity to any of the trial therapies or related substances.
- Having participated in other clinical trials with investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational trial.
- Prior TB treatment in the preceding 6 months
- Angina pectoris requiring treatment with nitroglycerin or other nitrates
- Cardiac arrhythmia requiring medication, or any clinically significant ECG abnormality, in the opinion of the investigator
- History of unstable Diabetes Mellitus requiring hospitalization for hyper- or hypo-glycaemia within the past year prior to start of screening.
- Use of systemic corticosteroids within the past 28 days.
- Patients requiring treatment with medications not compatible with rifampin, such as HIV-1 protease inhibitors
- Patients requiring treatment with antidepressants, including MAO inhibitors and SSRIs.
Subjects with any of the following abnormal laboratory values:
- HBsAg positive
- creatinine >2 mg/dL
- hemoglobin <8 g/dL
- platelets <100x109 cells/L
- serum potassium <3.5 mM/L
- alanine aminotransferase (ALT) ≥2.0 x ULN
- alkaline phosphatase (AP) >5.0 x ULN
- total bilirubin >1.5 mg/dL
- random blood glucose >200 mg/dL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 (S1200BP)
Sutezolid 1200mg QD plus bedaquiline and pretomanid for 4 months
|
Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
Pretomanid will be given at its approved dose
Bedaquiline will be given at its approved dose
|
Experimental: Arm 2 (S1600BP)
Sutezolid 1600mg QD plus bedaquiline and pretomanid for 4 months
|
Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
Pretomanid will be given at its approved dose
Bedaquiline will be given at its approved dose
|
Experimental: Arm 3 (S1600BPN)
Sutezolid 1600mg QD plus bedaquiline pretomanid and N-acetyl cysteine for 4 months
|
Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
Pretomanid will be given at its approved dose
Bedaquiline will be given at its approved dose
NAC will be given at a dose of 1800 mg BID in arm 3
Other Names:
|
Active Comparator: Arm 4 (HRZE)
Rifafour (2HRZE/4HR)
|
Fixed dose combination tablets for TB treatment will be given at approved doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients achieving durable (non-relapsing) cure
Time Frame: Assessed after 1 year of post-treatment follow-up
|
Assessed after 1 year of post-treatment follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects with TE ALT increases, graded according to severity
Time Frame: From day 1 through 4 weeks post end-of-treatment
|
From day 1 through 4 weeks post end-of-treatment
|
The proportion of subjects with TE increases in transaminases and bilirubin meeting Hy's criteria for serious liver injury
Time Frame: From day 1 through 4 weeks post end-of-treatment
|
From day 1 through 4 weeks post end-of-treatment
|
The proportion of subjects with TE AEs, according to seriousness
Time Frame: From day 1 through 4 weeks post end-of-treatment
|
From day 1 through 4 weeks post end-of-treatment
|
The number of TE AEs per treatment arm, according to seriousness
Time Frame: From day 1 through 4 weeks post end-of-treatment
|
From day 1 through 4 weeks post end-of-treatment
|
The proportion of subjects requiring temporary or permanent treatment discontinuation due to safety or tolerability concerns
Time Frame: From day 1 through 4 weeks post end-of-treatment
|
From day 1 through 4 weeks post end-of-treatment
|
FEV1 and FVC at 1, 2, 6, and 18 months after initiation of treatment
Time Frame: 1, 2, 6, and 18 months after initiation of treatment
|
1, 2, 6, and 18 months after initiation of treatment
|
FEV1 and FVC slope during 6 and 18 months after initiation of treatment
Time Frame: 6 and 18 months after initiation of treatment
|
6 and 18 months after initiation of treatment
|
FEV1/FVC ratio at 1, 2, 6, and 18 months after initiation of treatment
Time Frame: 1, 2, 6, and 18 months after initiation of treatment
|
1, 2, 6, and 18 months after initiation of treatment
|
The proportion of subjects with sputum cultures showing growth of MTB at 1, 2, 3, and 4 months after initiation of treatment
Time Frame: 1, 2, 3, and 4 months after initiation of treatment
|
1, 2, 3, and 4 months after initiation of treatment
|
The hazard ratio for stable culture conversion through the 4th month of treatment
Time Frame: through the 4th month of treatment
|
through the 4th month of treatment
|
The proportion of subjects with treatment failure
Time Frame: More than 1 specimen showing growth of MTB during the final 6 weeks of treatment
|
More than 1 specimen showing growth of MTB during the final 6 weeks of treatment
|
The proportion of subjects with relapse
Time Frame: At week 72 for the control arm and at week 64 for the experimental arms
|
At week 72 for the control arm and at week 64 for the experimental arms
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects with non-TB cardiac or pulmonary AEs during the 18 months after TB diagnosis, according to seriousness.
Time Frame: During the 18 months after TB diagnosis
|
During the 18 months after TB diagnosis
|
The plasma concentration (AUC) of sutezolid and its main metabolite
Time Frame: Month 1
|
Month 1
|
The plasma concentration (Cmax and Cmin) of sutezolid and its main metabolite
Time Frame: Month 1
|
Month 1
|
The plasma concentration (T>MIC) of sutezolid and its main metabolite
Time Frame: Month 1
|
Month 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Professor Robert Wallis, MD, The Aurum Institute NPC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2023
Primary Completion (Estimated)
September 30, 2025
Study Completion (Estimated)
September 30, 2025
Study Registration Dates
First Submitted
December 18, 2022
First Submitted That Met QC Criteria
January 13, 2023
First Posted (Actual)
January 17, 2023
Study Record Updates
Last Update Posted (Estimated)
May 15, 2024
Last Update Submitted That Met QC Criteria
May 14, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Anti-Bacterial Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Antitubercular Agents
- Free Radical Scavengers
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
- Bedaquiline
Other Study ID Numbers
- AUR1-1-312
- 24206 (Registry Identifier: Pan African Clinical Trials Registry (PACTR))
- 6986 (Registry Identifier: South African Clinical Trials Registry (SANCTR))
- RIA2019AMR-2647 (Other Grant/Funding Number: EDCTP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Sutezolid
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
Bill & Melinda Gates Medical Research InstituteGlobal Alliance for TB Drug Development; Janssen Pharmaceutica; Otsuka Pharmaceutical...RecruitingPulmonary TuberculosisSouth Africa, Philippines
-
Michael HoelscherRadboud University Medical Center; German Federal Ministry of Education and... and other collaboratorsCompletedPulmonary Tuberculosis | Other Specified Pulmonary TuberculosisSouth Africa, Tanzania
-
National Institute of Allergy and Infectious Diseases...TB AllianceNot yet recruitingPulmonary TuberculosisBotswana, Brazil, Haiti, India, Kenya, Malawi, Mexico, Peru, Philippines, South Africa, Thailand, Uganda, Zimbabwe